REFERENCES

1. Dorsey ER, Bloem BR. The Parkinson pandemic - a call to action. JAMA Neurol 2018;75:9-10.

2. Shahmoradian SH, Lewis AJ, Genoud C, et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci 2019;22:1099-109.

3. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006;396:67-72.

4. Borghammer P. The α-synuclein origin and connectome model (SOC model) of Parkinson’s disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J Parkinsons Dis 2021;11:455-74.

5. Solinas M, Ferré S, You ZB, Karcz-kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 2002;22:6321-4.

6. Devasagayam TP, Kamat JP, Mohan H, Kesavan PC. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta 1996;1282:63-70.

7. Schepici G, Silvestro S, Bramanti P, Mazzon E. Caffeine: an overview of its beneficial effects in experimental models and clinical trials of Parkinson’s disease. Int J Mol Sci 2020;21:4766.

8. Kolahdouzan M, Hamadeh MJ. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neurosci Ther 2017;23:272-90.

9. Olopade FE, Femi-Akinlosotu OM, Adekanmbi AJ, Ighogboja OO, Shokunbi MT. Chronic caffeine ingestion improves motor function and increases dendritic length and arborization in the motor cortex, striatum, and cerebellum. J Caffeine Adenosine Res 2021;11:3-14.

10. Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V. Adenosine receptors: expression, function and regulation. Int J Mol Sci 2014;15:2024-52.

11. Fredholm BB, Svenningsson P. Why target brain adenosine receptors? Parkinsonism Relat Disord 2020;80 Suppl 1:S3-6.

12. Camandola S, Plick N, Mattson MP. Impact of coffee and cacao purine metabolites on neuroplasticity and neurodegenerative disease. Neurochem Res 2019;44:214-27.

13. Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease? Parkinsonism Relat Disord 2020;80 Suppl 1:S45-53.

14. Ribeiro JA, Sebastião AM. Caffeine and adenosine. J Alzheimers Dis 2010;20 Suppl 1:S3-15.

15. Forth W, Adam O. Coffein: Umgang mit einem Genussmittel, das auch pharmakologische Wirkungen entfalten kann. Dtsch Arztebl 2001;98:2816.

16. Schwarzschild MA, Xu K, Oztas E, et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease. Neurology 2003;61:S55-61.

17. Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson’s disease. J Neurol Sci 2006;248:9-15.

18. Chen X, Ghiribi O, Geiger JD. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer’s and Parkinson’s disease. J Alzheimers Dis 2010;20:S127-41.

19. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9.

20. Paganini-Hill A. Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001;20:118-24.

21. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 2003;60:790-5.

22. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson’s disease: a study in Swedish twins. Ann Neurol 2005;57:27-33.

23. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord 2007;22:2242-8.

24. Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol 2008;167:553-60.

25. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 2008;23:88-95.

26. Sääksjärvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Männistö S. Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr 2008;62:908-15.

27. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012;175:1200-7.

28. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int 2014;14:430-9.

29. Bakshi R, Macklin EA, Hung AY, et al. Associations of lower caffeine intake and plasma urate levels with idiopathic Parkinson’s disease in the harvard biomarkers study. J Parkinsons Dis 2020;10:505-10.

30. Altman RD, Lang AE, Postuma RB. Caffeine in Parkinson’s disease: a pilot open-label, dose-escalation study. Mov Disord 2011;26:2427-31.

31. Simon DK, Wu C, Tilley BC, et al. Caffeine and progression of Parkinson disease: a deleterious interaction with creatine. Clin Neuropharmacol 2015;38:163-9.

32. Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): a randomized trial. Neurology 2017;89:1795-803.

33. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-8.

34. Fujimaki M, Saiki S, Li Y, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018;90:e404-11.

35. Ohmichi T, Kasai T, Kosaka T, et al. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson’s disease. PLoS One 2018;13:e0201260.

36. Ohmichi T, Kasai T, Shinomoto M, et al. Quantification of blood caffeine levels in patients with Parkinson’s disease and multiple system atrophy by caffeine ELISA. Front Neurol 2020;11:580127.

37. Crotty GF, Maciuca R, Macklin EA, et al. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: a metabolomic study. Neurology 2020;95:e3428-37.

38. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-96.

39. Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A2A receptor occupancy by caffeine after coffee intake in Parkinson’s disease. Mov Disord 2022;37:853-7.

40. Hauser RA, Hattori N, Fernandez H, et al. Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson’s disease: a pooled analysis of 8 phase 2b/3 trials. J Parkinsons Dis 2021;11:1663-75.

41. Wolz M, Kaminsky A, Löhle M, Koch R, Storch A, Reichmann H. Chocolate consumption is increased in Parkinson’s disease. Results from a self-questionnaire study. J Neurol 2009;256:488-92.

42. Wolz M, Schleiffer C, Klingelhöfer L, et al. Comparison of chocolate to cacao-free white chocolate in Parkinson’s disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial. J Neurol 2012;259:2447-51.